Analytical performance of OncoPrism-HNSCC, an RNA-based assay to inform immune checkpoint inhibitor treatment decisions for recurrent/metastatic head and neck squamous cell carcinoma.

OncoPrism scores did show a slight trend of decreasing as RNA input amount decreased (Fig. 3 A), and did differ significantly by RNA input amount using linear mixed effects models (Table 1 ).

also in 4,078 other papers

While there was a significant trend toward lower OncoPrism scores with lower RNA input, the effect size was small (Table 1 ).

also in 9,775 other papers